JP2010523660A5 - - Google Patents

Download PDF

Info

Publication number
JP2010523660A5
JP2010523660A5 JP2010503027A JP2010503027A JP2010523660A5 JP 2010523660 A5 JP2010523660 A5 JP 2010523660A5 JP 2010503027 A JP2010503027 A JP 2010503027A JP 2010503027 A JP2010503027 A JP 2010503027A JP 2010523660 A5 JP2010523660 A5 JP 2010523660A5
Authority
JP
Japan
Prior art keywords
use according
cell carcinoma
renal cell
papillary renal
cci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010503027A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523660A (ja
JP5908669B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/004501 external-priority patent/WO2008124125A1/en
Publication of JP2010523660A publication Critical patent/JP2010523660A/ja
Publication of JP2010523660A5 publication Critical patent/JP2010523660A5/ja
Application granted granted Critical
Publication of JP5908669B2 publication Critical patent/JP5908669B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010503027A 2007-04-10 2008-04-08 乳頭状腎細胞癌におけるテムシロリムス（Ｔｅｍｓｉｒｏｌｉｍｕｓ）の抗腫瘍活性 Active JP5908669B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92275907P 2007-04-10 2007-04-10
US60/922,759 2007-04-10
PCT/US2008/004501 WO2008124125A1 (en) 2007-04-10 2008-04-08 Anti-tumor activity of temsirolimus in papillary renal cell cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014259703A Division JP2015083595A (ja) 2007-04-10 2014-12-24 乳頭状腎細胞癌におけるテムシロリムス（Ｔｅｍｓｉｒｏｌｉｍｕｓ）の抗腫瘍活性

Publications (3)

Publication Number Publication Date
JP2010523660A JP2010523660A (ja) 2010-07-15
JP2010523660A5 true JP2010523660A5 (enExample) 2011-05-19
JP5908669B2 JP5908669B2 (ja) 2016-04-26

Family

ID=39619123

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010503027A Active JP5908669B2 (ja) 2007-04-10 2008-04-08 乳頭状腎細胞癌におけるテムシロリムス（Ｔｅｍｓｉｒｏｌｉｍｕｓ）の抗腫瘍活性
JP2014259703A Withdrawn JP2015083595A (ja) 2007-04-10 2014-12-24 乳頭状腎細胞癌におけるテムシロリムス（Ｔｅｍｓｉｒｏｌｉｍｕｓ）の抗腫瘍活性

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014259703A Withdrawn JP2015083595A (ja) 2007-04-10 2014-12-24 乳頭状腎細胞癌におけるテムシロリムス（Ｔｅｍｓｉｒｏｌｉｍｕｓ）の抗腫瘍活性

Country Status (23)

Country Link
US (1) US8791097B2 (enExample)
EP (5) EP3398597A1 (enExample)
JP (2) JP5908669B2 (enExample)
KR (2) KR20150002887A (enExample)
CN (2) CN105769861A (enExample)
AU (1) AU2008236621B2 (enExample)
CA (1) CA2681451C (enExample)
CL (1) CL2008001009A1 (enExample)
CY (2) CY1116492T1 (enExample)
DK (2) DK2462934T3 (enExample)
ES (2) ES2586739T3 (enExample)
HR (2) HRP20150678T1 (enExample)
HU (2) HUE029052T2 (enExample)
IL (1) IL200835A (enExample)
MX (1) MX2009010954A (enExample)
PA (1) PA8776101A1 (enExample)
PL (2) PL2462934T3 (enExample)
PT (2) PT2462934T (enExample)
RU (1) RU2501559C2 (enExample)
SI (2) SI2462934T1 (enExample)
TW (1) TW200901989A (enExample)
WO (1) WO2008124125A1 (enExample)
ZA (1) ZA200907063B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
EP2550964A1 (en) * 2011-07-26 2013-01-30 Universitat Pompeu-Fabra Temsirolimus for use in the prevention and/or treatment of a delta 9-tetrahydrocannabinol-induced anxiety disorder
US10765665B2 (en) 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
CN108143732A (zh) * 2017-12-19 2018-06-12 江南大学 雷帕霉素和ω-3脂肪酸在制备治疗肾癌的药物中的用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5023264A (en) 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
BR0009644A (pt) * 1999-04-08 2002-01-08 Schering Corp Tratamento de carcinoma de célula renal
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
US20020198137A1 (en) 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
AU2003254168A1 (en) 2002-07-30 2004-02-16 Wyeth Parenteral formulations containing a rapamycin hydroxyester
DE60324609D1 (de) 2002-09-17 2008-12-18 Wyeth Corp GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779
UA83484C2 (uk) 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
US20040258662A1 (en) 2003-04-22 2004-12-23 Wyeth Antineoplastic agents
CA2523798A1 (en) * 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
PT1658295E (pt) 2003-08-07 2007-09-25 Wyeth Corp Síntese regiosselectiva de cci-779
AR047988A1 (es) 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer

Similar Documents

Publication Publication Date Title
JP2012193216A5 (enExample)
JP2011515481A5 (enExample)
CA2683786C (en) Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects
JP2013527232A5 (enExample)
NZ604029A (en) Methods of treating bladder cancer
MX2022003132A (es) Composiciones de corticoesteroides administradas oralmente.
CA2633594C (en) Means and methods for the treatment of tumorous diseases
JP2013505205A5 (enExample)
MX2010010026A (es) Agente para tratar enfermedad.
JP2012506448A5 (enExample)
JP2011511786A5 (enExample)
JP2015212268A5 (enExample)
JP2011079858A5 (enExample)
JP2011252020A5 (enExample)
JP2012515184A5 (enExample)
MX356808B (es) Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia.
BR112012003283A2 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
JP2013530208A5 (enExample)
JP2010528091A5 (enExample)
MX338975B (es) Composicion farmaceutica que contiene sales de citrato y bicarbonato, y su uso para el tratamiento de la cistinuria.
WO2008075320A3 (en) Antilipidemic pharmaceutical compositions and process for preparation thereof
JP2007119497A5 (enExample)
JP2013540734A5 (enExample)
JP2009539916A5 (enExample)
HK1200354A1 (en) Combination therapy for chemoresistant cancers